Orchestra BioMed Holdings, Inc. OBIO
Medicinal Chemicals and Botanical Products · IPO 2020 · data as of November 13, 2026
Orchestra BioMed Holdings, Inc. (OBIO) is a healthcare company listed in the US with a market value of about $571M. In the twelve months to September 30, 2026 it had revenue of $31M and net income of -$58M, a net margin of -187.0%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -73%.
About Orchestra BioMed
Orchestra BioMed is listed in the US and classified in medicinal chemicals and botanical products, IPO year 2020. Revenue went from $4M in 2022 to $33M in 2025, growth of about 111.6% a year. It was profitable in 0 of the last 5 years in our data. Its share count rose by 219% over three years (dilution for shareholders). It spends 174% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 5 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $31M | $33M | $3M | $3M | $4M | — |
| Net income | -$58M | -$53M | -$61M | -$49M | -$34M | -$378753 |
| Free cash flow | -$64M | -$49M | -$51M | -$46M | -$30M | — |
| EPS (diluted) | $-0.75 | $-1.11 | $-1.66 | $-1.48 | $-2.24 | $-0.26 |
| Net margin | -187.0% | -157.4% | -2313.3% | -1779.7% | -951.3% | — |
| ROIC | — | -58.2% | -101.2% | -58.4% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $12.83, 77% above the current price; targets range from $10.00 to $20.00; the consensus rating is “Strong buy”; expected EPS is $-1.33 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Orchestra BioMed pay a dividend?
Not currently.
Is Orchestra BioMed a good stock to buy?
We do not give buy or sell advice. Orchestra BioMed scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.